Advancing Research on Alpha-1 Lung Disease

The Astraeus Study is enrolling patients now

Researchers are now testing an investigational drug taken as a tablet to determine if it is safe and if it has the potential to reduce lung damage and slow the progression of lung disease caused by Alpha-1 Antitrypsin Deficiency. As part of this research, we’re enlisting patients to participate in a clinical trial of the study drug, alvelestat.

Frequently Asked Questions

The study is open to people who meet very specific criteria.

Click on the “See if You qualify” button to walk through some of the preliminary eligibility criteria. If it looks as if the study might be a good fit for you, the Study Centre will be in touch with you and will go over the requirements with you in detail.

No. The study will use a common scientific method of dividing study participants into different groups and comparing their results. Two groups will receive the study drug (at two different strengths), and the third group will receive a placebo as the “control group”. The placebo is a dummy pill that looks the same as the study drug, but provides no treatment.

Participants will be assigned to one of these groups randomly (by chance, like flipping a coin). So, in the Astraeus Study, participants will have a 66 percent (2 in 3) chance of receiving alvelestat at one of the two doses and a 33 percent (1 in 3) chance of receiving the placebo.

There are three stages to the Astraeus Study, lasting a total of 20 weeks:

Screening. During this period of about 28 days, the study doctor will perform various tests to confirm that you are eligible to participate. This may involve making several visits to the study clinic.

Treatment. You will take the study drug or the placebo for 12 weeks, twice a day. You will need to visit the study clinic about seven times during this period and occasionally speak with the study doctor or nurse by phone. During your visits, the study doctor will examine you and perform several tests to monitor any changes in your health.

Follow up. At week 16, you will return to the Study Centre for a final assessment of your health.

No. All study-related visits, testing, and the study drug will be provided to participants at no cost.

You may also be compensated for participation depending on the country in which you live, and out-of-pocket expenses related to attending study visits may be reimbursed.

Click here to see if there is a Study Centre near you and to answer a few preliminary questions to see if you might be eligible to participate.

See if You Qualify